1. Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? FASEB J. 2003; 17(3): 349-368. doi: 10.1096/ fj.02-0473rev
2. Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K. Protein kinase CK2 signal in neoplasia. Histol Histopathol. 2001; 16(2): 573-582.doi: 10.14670/HH-16.573
3. Miyata Y, Nishida E. CK2 controls multiple protein kinases by phosphorylating a kinase-targeting molecular chaperone, Cdc37. Mol Cell Biol. 2004; 24(9): 4065-4074. doi: 10.1128/ MCB.24.9.4065-4074.2004
4. Zhao M, Ma J, Zhu HY, et al. Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90. Mol Cancer. 2011; 10: 104. doi: 10.1186/1476-4598-10-104
5. Miyata Y, Nishida E. Evaluating CK2 activity with the antibody specific for the CK2-phosphorylated form of a kinase-targeting cochaperone Cdc37. Mol Cell Biochem. 2008; 316(1-2): 127-134. doi: 10.1007/s11010-008-9818-1
6. Di MG, Brustolon F, Pinna LA, Ruzzene M. Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells. Cell Mol Life Sci. 2009; 66(20): 3363-3373. doi: 10.1007/s00018-009-0108-1
7. Siddiqui-Jain A, Drygin D, Streiner N, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010; 70(24): 10288-10298. doi: 10.1158/0008-5472.CAN-10-1893
8. Shehata M, Schnabl S, Demirtas D, et al. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood. 2010; 116(14): 2513-2521. doi: 10.1182/blood-2009-10-248054
9. Barata JT. The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival. Adv Enzyme Regul. 2011; 51(1): 37-49. doi: 10.1016/j.advenzreg.2010.09.012
10. Kang NI, Yoon HY, Kim HA, et al. Protein kinase CK2/ PTEN pathway plays a key role in platelet-activating factor-mediated murine anaphylactic shock. J Immunol. 2011 1; 186(11): 6625-6632. doi: 10.4049/jimmunol.1100007
11. Chatterjee A, Chatterjee U, Ghosh MK. Activation of protein kinase CK2 attenuates FOXO3a functioning in a PML-dependent manner: implications in human prostate cancer. Cell Death Dis. 2013; 4: e543. doi: 10.1038/cddis.2013.63
12. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Traish AM, Mercurio F, Sonenshein GE. Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kappaB in breast cancer. Cancer Res. 2001; 61(9): 3810-3818.
13. Shen J, Channavajhala P, Seldin DC, Sonenshein GE. Phosphorylation by the protein kinase CK2 promotes calpain-mediated degradation of IkappaBalpha. J Immunol. 2001; 167(9): 4919-4925. doi: 10.4049/jimmunol.167.9.4919
14. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE. Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells. Cancer Res. 2002; 62(22): 6770-6778.
15. Kato T, Jr., Delhase M, Hoffmann A, Karin M. CK2 Is a CTerminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response. Mol Cell. 2003; 12(4): 829-839.doi: 10.1016/s10972765(03)00358-7
16. Cavin LG, Romieu-Mourez R, Panta GR, et al. Inhibition of CK2 activity by TGF-beta1 promotes IkappaB-alpha protein stabilization and apoptosis of immortalized hepatocytes. Hepatology. 2003; 38(6): 1540-1551. doi: 10.1016/j.hep.2003.09.019
17. Eddy SF, Guo S, Demicco EG, et al. Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells. Cancer Res. 2005; 65(24): 11375-11383. doi: 10.1158/0008-5472.CAN-05-1602
18. Piazza FA, Ruzzene M, Gurrieri C, et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood. 2006; 108(5): 1698-1707. doi: 10.1182/blood-2005-11-013672
19. Yu M, Yeh J, Van WC. Protein kinase casein kinase 2 mediates inhibitor-kappaB kinase and aberrant nuclear factorkappaB activation by serum factor(sin head and neck squamous carcinoma cells. Cancer Res. 2006; 66(13): 6722-6731. doi: 10.1158/0008-5472.CAN-05-3758
20. Parhar K, Morse J, Salh B. The role of protein kinase CK2 in intestinal epithelial cell inflammatory signaling. Int J Colorectal Dis. 2007; 22(6): 601-609. doi: 10.1007/s00384-006-0193-7
21. Hamacher R, Saur D, Fritsch R, Reichert M, Schmid RM, Schneider G. Casein kinase II inhibition induces apoptosis in pancreatic cancer cells. Oncol Rep. 2007; 18(3): 695-701. doi: 10.3892/or.18.3.695
22. Dominguez I, Sonenshein GE, Seldin DC. Protein kinase CK2 in health and disease: CK2 and its role in Wnt and NFkappaB signaling: linking development and cancer. Cell Mol Life Sci. 2009; 66(11-12): 1850-1857. doi: 10.1007/s00018-009- 9153-z
23. Brown MS, Diallo OT, Hu M, et al. CK2 modulation of NFkappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub50-nm nanocapsules. Clin Cancer Res. 2010; 16(8): 2295-2307. doi: 10.1158/1078-0432.CCR-09-3200
24. Tsuchiya Y, Asano T, Nakayama K, Kato T, Jr., Karin M, Kamata H. Nuclear IKKbeta is an adaptor protein for IkappaBalpha ubiquitination and degradation in UV-induced NF-kappaB activation. Mol Cell. 2010; 39(4): 570-582. doi: 10.1016/j.molcel.2010.07.030
25. Trembley JH, Unger GM, Tobolt DK, et al. Systemic administration of antisense oligonucleotides simultaneously targeting CK2alpha and alpha’ subunits reduces orthotopic xenograft prostate tumors in mice. Mol Cell Biochem. 2011; 356(1-2): 21- 35. doi: 10.1007/s11010-011-0943-x
26. Trembley JH, Unger GM, Korman VL, et al. Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells. Cancer Lett. 2012; 315(1): 48-58. doi: 10.1016/j.canlet.2011.10.007
27. Zheng Y, McFarland BC, Drygin D, et al. Targeting Protein Kinase CK2 Suppresses Pro-survival Signaling Pathways and Growth of Glioblastoma. Clin Cancer Res. 2013; 19(23): 6484- 6494. doi: 10.1158/1078-0432.CCR-13-0265
28. Mottet D, Ruys SP, Demazy C, Raes M, Michiels C. Role for casein kinase 2 in the regulation of HIF-1 activity. Int J Cancer. 2005; 117(5): 764-774. doi: 10.1002/ijc.21268
29. Hubert A, Paris S, Piret JP, Ninane N, Raes M, Michiels C. Casein kinase 2 inhibition decreases hypoxia-inducible factor-1 activity under hypoxia through elevated p53 protein level. J Cell Sci. 2006; 119(Pt 16): 3351-3362. doi: 10.1242/jcs.03069
30. Ampofo E, Kietzmann T, Zimmer A, Jakupovic M, Montenarh M, Gotz C. Phosphorylation of the von Hippel-Lindau protein (VHL by protein kinase CK2 reduces its protein stability and affects p53 and HIF-1alpha mediated transcription. Int J Biochem Cell Biol. 2010; 42(10): 1729-1735. doi: 10.1016/j. biocel.2010.07.008
31. Song DH, Sussman DJ, Seldin DC. Endogenous protein kinase CK2 participates in Wnt signaling in mammary epithelial cells. J Biol Chem. 2000; 275(31): 23790-23797. doi: 10.1074/ jbc.M909107199
32. Song DH, Dominguez I, Mizuno J, Kaut M, Mohr SC, Seldin DC. CK2 phosphorylation of the armadillo repeat region of betacatenin potentiates Wnt signaling. J Biol Chem. 2003; 278(26): 24018-24025. doi: 10.1074/jbc.M212260200
33. Seldin DC, Landesman-Bollag E, Farago M, Currier N, Lou D, Dominguez I. CK2 as a positive regulator of Wnt signalling and tumourigenesis. Mol Cell Biochem. 2005; 274(1-2): 63-67. doi: 10.1007/s11010-005-3078-0
34. Tapia JC, Torres VA, Rodriguez DA, Leyton L, Quest AF. Casein kinase 2 (CK2increases survivin expression via enhanced beta-catenin-T cell factor/lymphoid enhancer binding factor-dependent transcription. Proc Natl Acad Sci U S A. 2006; 103(41): 15079-15084. doi: 10.1073/pnas.0606845103
35. Wang S, Jones KA. CK2 controls the recruitment of Wnt regulators to target genes in vivo. Curr Biol. 2006; 16(22): 2239- 2244. doi: 10.1016/j.cub.2006.09.034
36. Lee AK, Ahn SG, Yoon JH, Kim SA. Sox4 stimulates sscatenin activity through induction of CK2. Oncol Rep. 2011; 25(2): 559-565. doi: 10.3892/or.2010.1091
37. Ponce DP, Maturana JL, Cabello P, et al. Phosphorylation of AKT/PKB by CK2 is necessary for the AKT-dependent upregulation of beta-catenin transcriptional activity. J Cell Physiol. 2011; 226(7): 1953-1959. doi: 10.1002/jcp.22527
38. Ponce DP, Yefi R, Cabello P, et al. CK2 functionally interacts with AKT/PKB to promote the beta-catenin-dependent expression of survivin and enhance cell survival. Mol Cell Biochem. 2011; 356(1-2): 127-132. doi: 10.1007/s11010-011-0965-4
39. Kim J, Hwan KS. CK2 Inhibitor CX-4945 Blocks TGFbeta1-Induced Epithelial-to-Mesenchymal Transition in A549 Human Lung Adenocarcinoma Cells. PLoS ONE. 2013; 8(9): e74342.. doi: 10.1371/journal.pone.0074342
40. Piazza FA, Ruzzene M, Gurrieri C, et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood. 2006; 108(5): 1698-1707. doi: 10.1182/blood-2005-11-013672
41. Lin YC, Hung MS, Lin CK, et al. CK2 inhibitors enhance the radiosensitivity of human non-small cell lung cancer cells through inhibition of stat3 activation. Cancer Biother Radiopharm. 2011; 26(3): 381-388. doi: 10.1089/cbr.2010.0917
42. Zhao M, Ma J, Zhu HY, et al. Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90. Mol Cancer. 2011; 10: 104. doi: 10.1186/1476-4598-10-104
43. Zhang S, Wang Y, Mao JH, et al. Inhibition of CK2alpha down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells. PLoS ONE. 2012; 7(6): e38996. doi: 10.1111/jcmm.12068
44. Zhang S, Long H, Yang YL, et al. Inhibition of CK2alpha down-regulates Notch1 signalling in lung cancer cells. J Cell Mol Med. 2013; 17(7): 854-862. doi: 10.1111/jcmm.12068
45. Ryu BJ, Baek SH, Kim J, et al. Anti-androgen receptor activity of apoptotic CK2 inhibitor CX4945 in human prostate cancer LNCap cells. Bioorg Med Chem Lett. 2012; 22(17): 5470-5474. doi: 10.1016/j.bmcl.2012.07.031
46. Yao K, Youn H, Gao X, et al. Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells. Prostate. 2012; 72(13): 1423-1430. doi: 10.1002/pros.22493
47. Gotz C, Bachmann C, Montenarh M. Inhibition of protein kinase CK2 leads to a modulation of androgen receptor dependent transcription in prostate cancer cells. Prostate. 2007; 67(2): 125-134. doi: 10.1002/pros.20471
48. Loizou JI, El-Khamisy SF, Zlatanou A, et al. The protein kinase CK2 facilitates repair of chromosomal DNA single-strand breaks. Cell. 2004; 117(1): 17-28. doi: 10.1016/s0092-8674- (04)00206-5
49. Parsons JL, Dianova II, Finch D, et al. XRCC1 phosphorylation by CK2 is required for its stability and efficient DNA repair. DNA Repair (Amst). 2010; 9(7): 835-841. doi: 10.1016/j.dnarep.2010.04.008
50. Strom CE, Mortusewicz O, Finch D, et al. CK2 phosphorylation of XRCC1 facilitates dissociation from DNA and single-strand break formation during base excision repair. DNA Repair (Amst). 2011; 10(9): 961-969. doi: 10.1016/j. dnarep.2011.07.004
51. Siddiqui-Jain A, Bliesath J, Macalino D, et al. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNAtargeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. Mol Cancer Ther. 2012; 11(4): 994-1005. doi: 10.1158/1535-7163.MCT-11-0613
52. Chapman JR, Jackson SP. Phospho-dependent interactions between NBS1 and MDC1 mediate chromatin retention of the MRN complex at sites of DNA damage. EMBO Rep. 2008; 9(8): 795-801. doi: 10.1038/embor.2008.103
53. Becherel OJ, Jakob B, Cherry AL, et al. CK2 phosphorylation-dependent interaction between aprataxin and MDC1 in the DNA damage response. Nucleic Acids Res. 2010; 38(5): 1489- 1503. doi: 10.1093/nar/gkp1149
54. Belguise K, Guo S, Yang S, et al. Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, slug, and an invasive phenotype. Cancer Res. 2007; 67(24): 11742-11750. doi: 10.1158/0008-5472.CAN07-2730
55. MacPherson MR, Molina P, Souchelnytskyi S, et al. Phosphorylation of serine 11 and serine 92 as new positive regulators of human Snail1 function: potential involvement of casein kinase-2 and the cAMP-activated kinase protein kinase A. Mol Biol Cell. 2010; 21(2): 244-253. doi: 10.1091/mbc.E09-06-0504
56. Su YW, Xie TX, Sano D, Myers JN. IL-6 stabilizes Twist and enhances tumor cell motility in head and neck cancer cells through activation of casein kinase 2. PLoS ONE. 2011; 6(4): e19412. doi: 10.1371/journal.pone.0019412
57. Zou J, Luo H, Zeng Q, Dong Z, Wu D, Liu L. Protein kinase CK2alpha is overexpressed in colorectal cancer and modulates cell proliferation and invasion via regulating EMT-related genes. J Transl Med. 2011; 9: 97. doi: 10.1186/1479-5876-9-97
58. Kim J, Hwan KS. CK2 Inhibitor CX-4945 Blocks TGFbeta1-Induced Epithelial-to-Mesenchymal Transition in A549 Human Lung Adenocarcinoma Cells. PLoS ONE. 2013; 8(9): e74342. doi: 10.1371/journal.pone.0074342
59. Deshiere A, Duchemin-Pelletier E, Spreux E, et al. Regulation of epithelial to mesenchymal transition: CK2beta on stage. Mol Cell Biochem. 2011; 356(1-2): 11-20. doi: 10.1007/s11010- 011-0942-y
60. Deshiere A, Duchemin-Pelletier E, Spreux E, et al. Unbalanced expression of CK2 kinase subunits is sufficient to drive epithelial-to-mesenchymal transition by Snail1 induction. Oncogene. 2013; 32(11): 1373-1383. doi: 10.1038/onc.2012.165
61. Siddiqui-Jain A, Drygin D, Streiner N, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010; 70(24): 10288-10298. doi: 10.1158/0008-5472.CAN-10-1893
62. Pierre F, Chua PC, O’Brien SE, et al. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Mol Cell Biochem. 2011; 356(1-2): 37-43. doi: 10.1007/s11010-011-0956-5
63. Siddiqui-Jain A, Bliesath J, Macalino D, et al. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNAtargeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. Mol Cancer Ther. 2012; 11(4): 994-1005. doi: 10.1158/1535-7163.MCT-11-0613
64. Song DH, Sussman DJ, Seldin DC. Endogenous protein kinase CK2 participates in Wnt signaling in mammary epithelial cells. J Biol Chem. 2000; 275(31): 23790-23797. doi: 10.1074/ jbc.M909107199
65. Liu LZ, Fang J, Zhou Q, Hu X, Shi X, Jiang BH. Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol Pharmacol. 2005; 68(3): 635-643. doi: 10.1124/mol.105.011254
66. Shukla S, Mishra A, Fu P, MacLennan GT, Resnick MI, Gupta S. Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice. FASEB J. 2005; 19(14): 2042-2044. doi: 10.1096/fj.053740fje
67. Fang J, Zhou Q, Liu LZ, et al. Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis. 2007; 28(4): 858-864. doi: 10.1093/carcin/bgl205
68. Hu XW, Meng D, Fang J. Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase. Carcinogenesis. 2008; 29(12): 2369-2376. doi: 10.1093/carcin/bgn244
69. Lamy S, Bedard V, Labbe D, et al. The dietary flavones apigenin and luteolin impair smooth muscle cell migration and VEGF expression through inhibition of PDGFR-beta phosphorylation. Cancer Prev Res (Phila). 2008; 1(6): 452-459. doi: 10.1158/1940-6207.CAPR-08-0072
70. King JC, Lu QY, Li G, et al. Evidence for activation of mutated p53 by apigenin in human pancreatic cancer. Biochim Biophys Acta. 2012; 1823(2): 593-604. doi: 10.1016/j. bbamcr.2011.12.008
71. Torkin R, Lavoie JF, Kaplan DR, Yeger H. Induction of caspase-dependent, p53-mediated apoptosis by apigenin in human neuroblastoma. Mol Cancer Ther. 2005; 4(1): 1-11.
72. Shukla S, Gupta S. Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft. Mol Cancer Ther. 2006; 5(4): 843-852. doi: 10.1158/1535-7163. MCT-05-0370
73. Chen D, Landis-Piwowar KR, Chen MS, Dou QP. Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts. Breast Cancer Res. 2007; 9(6): R80. doi: 10.1186/ bcr1797
74. Kaur P, Shukla S, Gupta S. Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: an in vitro and in vivo study. Carcinogenesis. 2008; 29(11): 2210-2217. doi: 10.1093/carcin/bgn201
75. Shukla S, Gupta S. Apigenin suppresses insulin-like growth factor I receptor signaling in human prostate cancer: an in vitro and in vivo study. Mol Carcinog. 2009; 48(3): 243-252. doi: 10.1002/mc.20475
76. Cai J, Zhao XL, Liu AW, Nian H, Zhang SH. Apigenin inhibits hepatoma cell growth through alteration of gene expression patterns. Phytomedicine. 2011; 18(5): 366-373. doi: 10.1016/j.phymed.2010.08.006
77. Wang QR, Yao XQ, Wen G, et al. Apigenin suppresses the growth of colorectal cancer xenografts via phosphorylation and up-regulated FADD expression. Oncol Lett. 2011; 2(1): 43-47.doi: 10.3892/ol.2010.215
78. Pandey M, Kaur P, Shukla S, Abbas A, Fu P, Gupta S. Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: in vitro and in vivo study. Mol Carcinog. 2012; 51(12): 952-962. doi: 10.1002/mc.20866
79. Budhraja A, Gao N, Zhang Z, et al. Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo. Mol Cancer Ther. 2012; 11(1): 132-142. doi: 10.1158/1535-7163.MCT-11-0343
80. Mafuvadze B, Liang Y, Besch-Williford C, Zhang X, Hyder SM. Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors. Horm Cancer. 2012; 3(4): 160-171. doi: 10.1007/s12672-012-0114-x
81. Gao AM, Ke ZP, Wang JN, Yang JY, Chen SY, Chen H. Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/ Nrf2 pathway. Carcinogenesis. 2013; 34(8): 1806-1814. doi: 10.1093/carcin/bgt108
82. Hussain AR, Khan AS, Ahmed SO, et al. Apigenin induces apoptosis via downregulation of S-phase kinase-associated protein 2-mediated induction of p27Kip1 in primary effusion lymphoma cells. Cell Prolif. 2010; 43(2): 170-183. doi: 10.1111/ j.1365-2184.2009.00662.x
83. He J, Xu Q, Wang M, et al. Oral Administration of Apigenin Inhibits Metastasis through AKT/P70S6K1/MMP-9 Pathway in Orthotopic Ovarian Tumor Model. Int J Mol Sci. 2012; 13(6): 7271-7282. doi: 10.3390/ijms13067271
84. Tong X, Pelling JC. Targeting the PI3K/Akt/mTOR axis by apigenin for cancer prevention. Anticancer Agents Med Chem. 2013; 13(7): 971-978. doi: 10.2174/18715206113139990119
85. Gao AM, Ke ZP, Wang JN, Yang JY, Chen SY, Chen H. Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/ Nrf2 pathway. Carcinogenesis. 2013; 34(8): 1806-1814. doi: 10.1093/carcin/bgt108
86. Chunhua L, Donglan L, Xiuqiong F, et al. Apigenin upregulates transgelin and inhibits invasion and migration of colorectal cancer through decreased phosphorylation of AKT. J Nutr Biochem. 2013; 24(10): 1766-1775. doi: 10.1016/j. jnutbio.2013.03.006
87. Osada M, Imaoka S, Funae Y. Apigenin suppresses the expression of VEGF, an important factor for angiogenesis, in endothelial cells via degradation of HIF-1alpha protein. FEBS Lett. 2004; 575(1-3): 59-63.doi: 10.1016/j.febslet.2004.08.036
88. Mottet D, Ruys SP, Demazy C, Raes M, Michiels C. Role for casein kinase 2 in the regulation of HIF-1 activity. Int J Cancer. 2005; 117(5): 764-774. doi: 10.1002/ijc.21268
89. Fang J, Zhou Q, Liu LZ, et al. Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis. 2007; 28(4): 858-864. doi: 10.1093/carcin/bgl205
90. Mirzoeva S, Kim ND, Chiu K, Franzen CA, Bergan RC, Pelling JC. Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. Mol Carcinog. 2008; 47(9): 686-700. doi: 10.1002/mc.20421
91. Melstrom LG, Salabat MR, Ding XZ, et al. Apigenin downregulates the hypoxia response genes: HIF-1alpha, GLUT-1, and VEGF in human pancreatic cancer cells. J Surg Res. 2011; 167(2): 173-181. doi: 10.1016/j.jss.2010.10.041
92. Gupta S, Afaq F, Mukhtar H. Involvement of nuclear factorkappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. Oncogene. 2002; 21(23): 3727-3738. doi: 10.1038/sj/onc/1205474
93. Lee SH, Ryu JK, Lee KY, et al. Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett. 2008; 259(1): 39-49. doi: 10.1016/j.canlet.2007.09.015
94. Seo HS, Choi HS, Kim SR, et al. Apigenin induces apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3 and NFkappaB signaling in HER2-overexpressing breast cancer cells. Mol Cell Biochem. 2012; 366(1-2): 319-334. doi: 10.1007/ s11010-012-1310-2
95. Johnson JL, Gonzalez de ME. Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro. Food Chem Toxicol. 2013; 60: 83-91. doi: 10.1016/j.fct.2013.07.036
96. Lamy S, Akla N, Ouanouki A, Lord-Dufour S, Beliveau R. Diet-derived polyphenols inhibit angiogenesis by modulating the interleukin-6/STAT3 pathway. Exp Cell Res. 2012; 318(13): 1586-1596. doi: 10.1016/j.yexcr.2012.04.004
97. Song DH, Sussman DJ, Seldin DC. Endogenous protein kinase CK2 participates in Wnt signaling in mammary epithelial cells. J Biol Chem. 2000; 275(31): 23790-23797. doi: 10.1074/ jbc.M909107199
98. Shukla S, MacLennan GT, Flask CA, et al. Blockade of betacatenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice. Cancer Res. 2007; 67(14): 6925-6935. doi: 10.1158/0008-5472.CAN-07-0717
99. Slusarz A, Shenouda NS, Sakla MS, et al. Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res. 2010; 70(8): 3382-3390. doi: 10.1158/0008- 5472.CAN-09-3012
100. Tsai CH, Lin FM, Yang YC, et al. Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clin Cancer Res. 2009; 15(17): 5435-5444. doi: 10.1158/1078-0432.CCR-09-0298
101. Lin FM, Chen LR, Lin EH, et al. Compounds from Wedelia chinensis synergistically suppress androgen activity and growth in prostate cancer cells. Carcinogenesis. 2007; 28(12): 2521- 2529. doi: 10.1093/carcin/bgm137
102. Cai X, Liu X. Inhibition of Thr-55 phosphorylation restores p53 nuclear localization and sensitizes cancer cells to DNA damage. Proc Natl Acad Sci U S A. 2008; 105(44): 16958-16963. doi: 10.1073/pnas.0804608105
103. Zhong Y, Krisanapun C, Lee SH, et al. Molecular targets of apigenin in colorectal cancer cells: involvement of p21, NAG-1 and p53. Eur J Cancer. 2010; 46(18): 3365-3374. doi: 10.1016/j.ejca.2010.07.007
104. Dixit D, Sharma V, Ghosh S, Mehta VS, Sen E. Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFalpha)-induced apoptosis through SIRT1 inhibition. Cell Death Dis. 2012; 3: e271. doi: 10.1038/cddis.2012.10
105. Choi EJ, Kim GH. Apigenin causes G(2)/M arrest associated with the modulation of p21(Cip1and Cdc2 and activates p53- dependent apoptosis pathway in human breast cancer SK-BR-3 cells. J Nutr Biochem. 2009; 20(4): 285-290. doi: 10.1016/j.jnutbio.2008.03.005
106. Shukla S, Gupta S. Apigenin-induced prostate cancer cell death is initiated by reactive oxygen species and p53 activation. Free Radic Biol Med. 2008; 44(10): 1833-1845. doi: 10.1016/j.freeradbiomed.2008.02.007
107. Chiang LC, Ng LT, Lin IC, Kuo PL, Lin CC. Anti-proliferative effect of apigenin and its apoptotic induction in human Hep G2 cells. Cancer Lett. 2006; 237(2): 207-214. doi: 10.1016/j. canlet.2005.06.002
108. Zheng PW, Chiang LC, Lin CC. Apigenin induced apoptosis through p53-dependent pathway in human cervical carcinoma cells. Life Sci. 2005; 76(12): 1367-1379. doi: 10.1016/j. lfs.2004.08.023
109. Takagaki N, Sowa Y, Oki T, Nakanishi R, Yogosawa S, Sakai T. Apigenin induces cell cycle arrest and p21/WAF1 expression in a p53-independent pathway. Int J Oncol. 2005; 26(1): 185-189. doi: 10.3892/ijo.26.1.185
110. Lolli G, Cozza G, Mazzorana M, et al. Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight. Biochemistry. 2012; 51(31): 6097-6107. doi: 10.1021/bi300531c
111. Attoub S, Hassan AH, Vanhoecke B, et al. Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells. Eur J Pharmacol. 2011; 651(1-3): 18-25. doi: 10.1016/j. ejphar.2010.10.063
112. Yang SF, Yang WE, Chang HR, Chu SC, Hsieh YS. Luteolin induces apoptosis in oral squamous cancer cells. J Dent Res. 2008; 87(4): 401-406. doi: 10.1177/154405910808700413
113. Chiu FL, Lin JK. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts. Prostate. 2008; 68(1): 61-71. doi: 10.1002/pros.20690
114. Bagli E, Stefaniotou M, Morbidelli L, et al. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3’-kinase activity. Cancer Res. 2004; 64(21): 7936-7946. doi: 10.1158/0008-5472.CAN-03-3104
115. Selvendiran K, Koga H, Ueno T, et al. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. Cancer Res. 2006; 66(9): 4826-4834. doi: 10.1158/0008-5472.CAN-05-4062
116. Shi R, Huang Q, Zhu X, et al. Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization. Mol Cancer Ther. 2007; 6(4): 1338-1347. doi: 10.1158/1535-7163.MCT-06-0638
117. Zhou Q, Yan B, Hu X, Li XB, Zhang J, Fang J. Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin. Mol Cancer Ther. 2009; 8(6): 1684-1691. doi: 10.1158/1535- 7163.MCT-09-0191
118. Hwang JT, Park OJ, Lee YK, et al. Anti-tumor effect of luteolin is accompanied by AMP-activated protein kinase and nuclear factor-kappaB modulation in HepG2 hepatocarcinoma cells. Int J Mol Med. 2011; 28(1): 25-31. doi: 10.3892/ijmm.2011.667
119. Tsai CH, Lin FM, Yang YC, et al. Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clin Cancer Res. 2009; 15(17): 5435-5444. doi: 10.1158/1078-0432.CCR-09-0298
120. Yan J, Wang Q, Zheng X, et al. Luteolin enhances TNFrelated apoptosis-inducing ligand’s anticancer activity in a lung cancer xenograft mouse model. Biochem Biophys Res Commun. 2012; 417(2): 842-846. doi: 10.1016/j.bbrc.2011.12.055
121. Lee EJ, Oh SY, Sung MK. Luteolin exerts anti-tumor activity through the suppression of epidermal growth factor receptor-mediated pathway in MDA-MB-231 ER-negative breast cancer cells. Food Chem Toxicol. 2012; 50(11): 4136-4143. doi: 10.1016/j.fct.2012.08.025
122. Pratheeshkumar P, Son YO, Budhraja A, et al. Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. PLoS ONE. 2012; 7(12): e52279. doi: 10.1371/journal.pone.0052279
123. Huang WW, Chiu YJ, Fan MJ, et al. Kaempferol induced apoptosis via endoplasmic reticulum stress and mitochondriadependent pathway in human osteosarcoma U-2 OS cells. Mol Nutr Food Res. 2010; 54(11): 1585-1595. doi: 10.1002/ mnfr.201000005
124. Khan N, Asim M, Afaq F, Abu ZM, Mukhtar H. A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res. 2008; 68(20): 8555-8563. doi: 10.1158/0008-5472.CAN-08-0240
125. Tripathi R, Samadder T, Gupta S, Surolia A, Shaha C. Anticancer activity of a combination of cisplatin and fisetin in embryonal carcinoma cells and xenograft tumors. Mol Cancer Ther. 2011; 10(2): 255-268. doi: 10.1158/1535-7163.MCT-10-0606
126. Ying TH, Yang SF, Tsai SJ, et al. Fisetin induces apoptosis in human cervical cancer HeLa cells through ERK1/2-mediated activation of caspase-8-/caspase-3-dependent pathway. Arch Toxicol. 2012; 86(2): 263-273. doi: 10.1007/s00204-011-0754-6
127. Zhou W, Kallifatidis G, Baumann B, et al. Dietary polyphenol quercetin targets pancreatic cancer stem cells. Int J Oncol. 2010; 37(3): 551-561. doi: 10.3892/ijo_00000704
128. Zhong X, Wu K, He S, Ma S, Kong L. Effects of quercetin on the proliferation and apoptosis in transplantation tumor of breast cancer in nude mice. Sichuan Da Xue Xue Bao Yi Xue Ban. 2003; 34(3): 439-442.
129. Ma ZS, Huynh TH, Ng CP, Do PT, Nguyen TH, Huynh H. Reduction of CWR22 prostate tumor xenograft growth by combined tamoxifen-quercetin treatment is associated with inhibition of angiogenesis and cellular proliferation. Int J Oncol. 2004; 24(5): 1297-1304. doi: 10.3892/ijo.24.5.1297
130. Dechsupa S, Kothan S, Vergote J, et al. Quercetin, Siamois 1 and Siamois 2 induce apoptosis in human breast cancer MDAmB-435 cells xenograft in vivo. Cancer Biol Ther. 2007; 6(1): 56-61. doi: 10.4161/cbt.6.1.3548
131. Sun ZJ, Chen G, Hu X, et al. Activation of PI3K/Akt/IKKalpha/NF-kappaB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: its inhibition by quercetin. Apoptosis. 2010; 15(7): 850-863. doi: 10.1007/s10495-010-0497-5
132. Cheng S, Gao N, Zhang Z, et al. Quercetin induces tumorselective apoptosis through downregulation of Mcl-1 and activation of Bax. Clin Cancer Res. 2010; 16(23): 5679-5691. doi: 10.1158/1078-0432.CCR-10-1565
133. Long Q, Xiel Y, Huang Y, et al. Induction of apoptosis and inhibition of angiogenesis by PEGylated liposomal quercetin in both cisplatin-sensitive and cisplatin-resistant ovarian cancers. J Biomed Nanotechnol. 2013; 9(6): 965-975. doi: http://dx.doi.org/10.1166/jbn.2013.1596
134. Huang CY, Chan CY, Chou IT, Lien CH, Hung HC, Lee MF. Quercetin induces growth arrest through activation of FOXO1 transcription factor in EGFR-overexpressing oral cancer cells. J Nutr Biochem. 2013; 24(9): 1596-1603. doi: 10.1016/j. jnutbio.2013.01.010
135. Chan ST, Yang NC, Huang CS, Liao JW, Yeh SL. Quercetin enhances the antitumor activity of trichostatin A through upregulation of p53 protein expression in vitro and in vivo. PLoS ONE. 2013; 8(1): e54255. doi: 10.1371/journal.pone.0054255
136. Wang G, Zhang J, Liu L, Sharma S, Dong Q. Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. PLoS ONE. 2012; 7(12): e51764. doi: 10.1371/journal.pone.0051764
137. Pratheeshkumar P, Budhraja A, Son YO, et al. Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting V EGFR- 2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS ONE. 2012; 7(10): e47516. doi: 10.1371/journal.pone.0047516
138. Gao X, Wang B, Wei X, et al. Anticancer effect and mechanism of polymer micelle-encapsulated quercetin on ovarian cancer. Nanoscale. 2012 21; 4(22): 7021-7030. doi: 10.1039/ c2nr32181e
139. Angst E, Park JL, Moro A, et al. The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo. Pancreas. 2013; 42(2): 223-229. doi: 10.1097/MPA.0b013e318264ccae
140. Kim HS, Wannatung T, Lee S, et al. Quercetin enhances hypoxia-mediated apoptosis via direct inhibition of AMPK activity in HCT116 colon cancer. Apoptosis. 2012; 17(9): 938-949. doi: 10.1007/s104950120719-0
141. Tan BJ, Liu Y, Chang KL, Lim BK, Chiu GN. Perorally active nanomicellar formulation of quercetin in the treatment of lung cancer. Int J Nanomedicine. 2012; 7: 651-661. doi: 10.2147/ IJN.S26538
142. Zheng SY, Li Y, Jiang D, Zhao J, Ge JF. Anticancer effect and apoptosis induction by quercetin in the human lung cancer cell line A-549. Mol Med Rep. 2012; 5(3): 822-826. doi: 10.3892/mmr.2011.726
143. Lin C, Yu Y, Zhao HG, Yang A, Yan H, Cui Y. Combination of quercetin with radiotherapy enhances tumor radiosensitivity in vitro and in vivo. Radiother Oncol. 2012; 104(3): 395-400. doi: 10.1016/j.radonc.2011.10.023
144. Wang K, Liu R, Li J, et al. Quercetin induces protective autophagy in gastric cancer cells: involvement of Akt-mTOR- and hypoxia-induced factor 1alpha-mediated signaling. Autophagy. 2011; 7(9): 966-978.doi: 10.4161/auto.7.9.15863
145. Wong MY, Chiu GN. Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model. Nanomedicine. 2011; 7(6): 834-840. doi: 10.1016/j.nano.2011.02.001
146. Sun F, Zheng XY, Ye J, Wu TT, Wang J, Chen W. Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo. Nutr Cancer. 2012; 64(4): 599- 606. doi: 10.1080/01635581.2012.665564
147. Valentova K, Vrba J, Bancirova M, Ulrichova J, Kren V. Isoquercitrin: pharmacology, toxicology, and metabolism. Food Chem Toxicol. 2014; 68: 267-282. doi: 10.1016/j. fct.2014.03.018
148. Murota K, Matsuda N, Kashino Y, et al. alpha-Oligoglucosylation of a sugar moiety enhances the bioavailability of quercetin glucosides in humans. Arch Biochem Biophys. 2010; 501(1): 91-97. doi: 10.1016/j.abb.2010.06.036
149. Makino T, Shimizu R, Kanemaru M, Suzuki Y, Moriwaki M, Mizukami H. Enzymatically modified isoquercitrin, alphaoligoglucosyl quercetin 3-O-glucoside, is absorbed more easily than other quercetin glycosides or aglycone after oral administration in rats. Biol Pharm Bull. 2009; 32(12): 2034-2040.doi: 10.1248/bpb.32.2034
150. Kawai M, Hirano T, Arimitsu J, et al. Effect of enzymatically modified isoquercitrin, a flavonoid, on symptoms of Japanese cedar pollinosis: a randomized double-blind placebo-controlled trial. Int Arch Allergy Immunol. 2009; 149(4): 359-368. doi: 10.1159/000205582
151. Motoyama K, Koyama H, Moriwaki M, et al. Atheroprotective and plaque-stabilizing effects of enzymatically modified isoquercitrin in atherogenic apoE-deficient mice. Nutrition. 2009; 25(4): 421-427. doi: 10.1016/j.nut.2008.08.013
152. Shia CS, Tsai SY, Kuo SC, Hou YC, Chao PD. Metabolism and pharmacokinetics of 3,3’,4’,7-tetrahydroxyflavone (fisetin), 5-hydroxyflavone, and 7-hydroxyflavone and antihemolysis effects of fisetin and its serum metabolites. J Agric Food Chem. 2009; 57(1): 83-89. doi: 10.1021/jf802378q
153. FISHMAN WH, ANLYAN AJ. The presence of high beta-glucuronidase activity in cancer tissue. J Biol Chem. 1947; 169(2): 449.
154. Bosslet K, Straub R, Blumrich M, et al. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res. 1998; 58(6): 1195-1201
155. Paigen K. Mammalian beta-glucuronidase: genetics, molecular biology, and cell biology. Prog Nucleic Acid Res Mol Biol. 1989; 37: 155-205.doi: 10.1016/s0079-6603(08)60698-4
156. Estrella V, Chen T, Lloyd M, et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013; 73(5): 1524-1535. doi: 10.1158/0008-5472.CAN-12- 2796
157. Murdter TE, Friedel G, Backman JT, et al. Dose optimization of a doxorubicin prodrug (HMR 1826in isolated perfused human lungs: low tumor pH promotes prodrug activation by beta-glucuronidase. J Pharmacol Exp Ther. 2002; 301(1): 223- 228. doi: 10.1124/jpet.301.1.223
158. Sperker B, Werner U, Murdter TE, et al. Expression and function of beta-glucuronidase in pancreatic cancer: potential role in drug targeting. Naunyn Schmiedebergs Arch Pharmacol. 2000; 362(2): 110-115. doi: 10.1007/s002100000260
159. de GM, Boven E, Scheeren HW, Haisma HJ, Pinedo HM. Beta-glucuronidase-mediated drug release. Curr Pharm Des. 2002; 8(15): 1391-1403. doi: 10.2174/1381612023394485
160. Yuan L, Wagatsuma C, Yoshida M, et al. Inhibition of human breast cancer growth by GCP (genistein combined polysaccharidein xenogeneic athymic mice: involvement of genistein biotransformation by beta-glucuronidase from tumor tissues. Mutat Res. 2003; 523-524: 55-62. doi: 10.1016/s0027-5107- (02)00321-4
161. Chen X, Wu B, Wang PG. Glucuronides in anti-cancer therapy. Curr Med Chem Anticancer Agents. 2003; 3(2): 139-150. doi: 10.2174/1568011033353470
162. Oi N, Hashimoto T, Kanazawa K. Metabolic conversion of dietary quercetin from its conjugate to active aglycone following the induction of hepatocarcinogenesis in fisher 344 rats. J Agric Food Chem. 2008; 56(2): 577-583. doi: 10.1021/jf072556c
163. Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett. 2008; 269(2): 315-325. doi: 10.1016/j.canlet.2008.03.046
164. Legigan T, Clarhaut J, Renoux B, et al. Synthesis and antitumor efficacy of a beta-glucuronidase-responsive albuminbinding prodrug of doxorubicin. J Med Chem. 2012; 55(9): 4516-4520.doi: 10.1021/jm300348r
165. Chen KC, Schmuck K, Tietze LF, Roffler SR. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue. Mol Pharm. 2013; 10(5): 1773- 1782. doi: 10.1021/mp300581u
166. Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med (wood). 2007; 232(2): 227-234.
167. Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005; 280(29): 26729-26734. doi: 10.1074/jbc.C500186200
168. Aoyagi S, Archer TK. Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol. 2005; 15(11): 565-567. doi: 10.1016/j.tcb.2005.09.003
169. Rao R, Fiskus W, Yang Y, et al. HDAC6 inhibition enhances 17-AAG–mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood. 2008; 112(5): 1886-1893. doi: 10.1182/blood2008-03-143644
170. Ai J, Wang Y, Dar JA, et al. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer. Mol Endocrinol. 2009; 23(12): 1963-1972. doi: 10.1210/me.2009- 0188
171. Gibbs A, Schwartzman J, Deng V, Alumkal J. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci U S A. 2009; 106(39): 16663-16668. doi: 10.1073/pnas.0908908106
172. Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J Biomed Biotechnol. 2011; 2011: 875824. doi: 10.1155/2011/875824
173. Kaliszczak M, Trousil S, Aberg O, Perumal M, Nguyen QD, Aboagye EO. A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth. Br J Cancer. 2013; 108(2): 342-350. doi: 10.1038/bjc.2012.576
174. Wang P, Henning SM, Heber D, Vadgama JV. Sensitization to docetaxel in prostate cancer cells by green tea and quercetin. J Nutr Biochem. 2015. doi: 10.1016/j.jnutbio.2014.11.017
175. Chen FY, Cao LF, Wan HX, et al. Quercetin enhances adriamycin cytotoxicity through induction of apoptosis and regulation of mitogen-activated protein kinase/extracellular signal-regulated kinase/c-Jun N-terminal kinase signaling in multidrug-resistant leukemia K562 cells. Mol Med Rep. 2015; 11(1): 341-348. doi: 10.3892/mmr.2014.2734
176. Maciejczyk A, Surowiak P. Quercetin inhibits proliferation and increases sensitivity of ovarian cancer cells to cisplatin and paclitaxel. Ginekol Pol. 2013; 84(7): 590-595.doi: 10.17772/gp/1609
177. Han Y, Yu H, Wang J, Ren Y, Su X, Shi Y. Quercetin alleviates myocyte toxic and sensitizes anti-leukemic effect of adriamycin. Hematology. 2014. doi: http://dx.doi.org/10.1179/1607845414y.0000000198
178. Orsolic N, Car N. Quercetin and hyperthermia modulate cisplatin-induced DNA damage in tumor and normal tissues in vivo. Tumour Biol. 2014; 35(7): 6445-6454. doi: 10.1007/ s13277-014-1843-y
179. Papiez MA. The effect of quercetin on oxidative DNA damage and myelosuppression induced by etoposide in bone marrow cells of rats. Acta Biochim Pol. 2014; 61(1): 7-11.
180. Mahoney SE, Davis JM, Murphy EA, McClellan JL, Pena MM. Dietary quercetin reduces chemotherapy-induced fatigue in mice. Integr Cancer Ther. 2014; 13(5): 417-424. doi: 10.1177/1534735414523315
181. Azevedo MI, Pereira AF, Nogueira RB, et al. The antioxidant effects of the flavonoids rutin and quercetin inhibit oxaliplatin-induced chronic painful peripheral neuropathy. Mol Pain. 2013; 9: 53. doi: 10.1186/1744-8069-9-53
182. Lou DY, Dominguez I, Toselli P, Landesman-Bollag E, O’Brien C, Seldin DC. The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development. Mol Cell Biol. 2008; 28(1): 131-139. doi: 10.1128/MCB.01119-07
183. Landesman-Bollag E, Belkina A, Hovey B, Connors E, Cox C, Seldin DC. Developmental and growth defects in mice with combined deficiency of CK2 catalytic genes. Mol Cell Biochem. 2011; 356(1-2): 227-231. doi: 10.1007/s11010-011-0967-2
184. Hasumura M, Yasuhara K, Tamura T, Imai T, Mitsumori K, Hirose M. Evaluation of the toxicity of enzymatically decomposed rutin with 13-weeks dietary administration to Wistar rats. Food Chem Toxicol. 2004; 42(3): 439-444. doi: 10.1016/j. fct.2003.10.006